- Home
- SON vs DNTH Comparison
SON vs DNTH Comparison
Compare SON & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SON | DNTH |
|---|---|---|
| Founded | 1899 | 2015 |
| Country | United States | United States |
| Employees | N/A | 92 |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.8B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SON | DNTH |
|---|---|---|
| Price | $48.41 | $87.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $60.50 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.2M | 753.9K |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ 510.30 | N/A |
| EPS | ★ 10.07 | N/A |
| Revenue | ★ $7,518,753,000.00 | $2,036,000.00 |
| Revenue This Year | $0.10 | N/A |
| Revenue Next Year | $1.82 | $29.48 |
| P/E Ratio | $4.85 | ★ N/A |
| Revenue Growth | ★ 41.72 | N/A |
| 52 Week Low | $38.65 | $16.77 |
| 52 Week High | $58.44 | $96.50 |
Technical Indicators
Market Signals| Indicator | SON | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 34.37 | 54.75 |
| Support Level | $43.93 | $33.94 |
| Resistance Level | $48.73 | $88.45 |
| Average True Range (ATR) | 1.78 | 3.74 |
| MACD | -0.86 | -1.19 |
| Stochastic Oscillator | 17.82 | 33.16 |
Price Performance
Historical ComparisonAbout SON Sonoco Products Company
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.